No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Cinryze is a brand of immune disorder drugs used to treat hereditary angioedema (HAE). It is a rare, genetic disorder that causes episodes of swelling in the face, extremities, gastrointestinal tract, and airway. Cinryze is a C1 esterase inhibitor (C1-INH) that works by replacing the missing or deficient C1-INH protein in the body. It is administered intravenously and is used to prevent and treat HAE attacks. Cinryze is the only FDA-approved C1-INH therapy for HAE and is the only therapy approved for routine prophylaxis.
The Cinryze market is composed of a variety of companies that produce and distribute C1-INH therapies. These companies include Shire, CSL Behring, Pharming Group, and ViroPharma. Additionally, there are several generic versions of C1-INH therapies available in the market. Show Less Read more
